ArticlePharmacoEconomics2006

Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.

George Dranitsaris et al.PubMed ↗Publisher ↗

No numbers read from the abstract.